Screener
Halozyme Therapeutics HALO Free cash flow margin
Free cash flow margin at other companies
Other financials
Where this comes from
Calculated from Halozyme Therapeutics’s reported figures.
Based on trailing twelve months.
The source filing: Halozyme Therapeutics’s 10-Q, filed August 6, 2026. Open the filing →
- Filed
- Aug 6, 2026, 4:11 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001159036-26-000104
FAQ
- What is Halozyme Therapeutics's free cash flow margin?
- Halozyme Therapeutics (HALO) reported free cash flow margin of 48.5% in Q2 2026.
- How has Halozyme Therapeutics's free cash flow margin changed year-over-year?
- Halozyme Therapeutics's free cash flow margin increased by 5.6% year-over-year, from 45.9% to 48.5%.
- What is the long-term trend for Halozyme Therapeutics's free cash flow margin?
- Over 5 years (2020 to 2025), Halozyme Therapeutics's free cash flow margin has grown at a 18.5% compound annual growth rate (CAGR), from 19.8% to 46.2%.
- What does free cash flow margin mean?
- Free cash flow (operating cash flow minus capital expenditures) as a percentage of revenue, trailing twelve months. Measures how efficiently revenue converts into discretionary cash.
Ask your AI about Halozyme Therapeutics's free cash flow margin.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude